Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Pharmacol. 2009 Jun;9(3):336-40. doi: 10.1016/j.coph.2009.04.005. Epub 2009 May 8.

Autoimmune disorders of the neuromuscular junction.

Author information

1
Department of Clinical Neurology, University of Oxford, Oxford OX3 9DS, UK. blang@hammer.imm.ox.ac.uk

Abstract

The neuromuscular junction lies beyond the protection of the blood-brain barrier and is particularly vulnerable to antibody-mediated attack. In myasthenia gravis, the expression of acetylcholine receptors (AChRs) in the thymus is under the control of the autoimmune regulator protein (AIRE), and polymorphisms in the AChR correlate with early onset of disease. In some 'AChR seronegative' patients, thymic abnormalities associated with complement-activating antibodies binding only clustered AChRs have been demonstrated, and in others anti-muscle-specific kinase (MuSK) antibodies that show pathogenic effects in vivo. In Guillain-Barré syndrome, newly described antibodies bind to complex gangliosides. General immunosuppression is still the main treatment, but novel treatments that reduce complement-mediated damage or inhibit the binding of pathogenic antibodies are beginning to look promising.

PMID:
19428298
DOI:
10.1016/j.coph.2009.04.005
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center